论文部分内容阅读
目的:观察静脉滴注奥美拉唑致肝硬化患者白细胞数减少的情况。方法:选择肝硬化患者82例(观察组)和非肝硬化患者210例(对照组),采用奥美拉唑40 mg静脉滴注,每天2次,7~14天为1个疗程。分别于用药前、用药后3天、用药后1周、停药后进行血常规检查。结果:观察组中14.6%用药后出现白细胞数下降,对照组中仅1.0%出现白细胞数下降。结论:奥美拉唑可导致肝硬化患者白细胞数显著降低。
Objective: To observe the decrease of white blood cell count in patients with cirrhosis caused by intravenous infusion of omeprazole. Methods: 82 patients with cirrhosis (observation group) and 210 patients without cirrhosis (control group) were enrolled in this study. Omeprazole 40 mg was given intravenously twice daily for 7-14 days as a course of treatment. Respectively before medication, 3 days after treatment, 1 week after treatment, after stopping the blood test. Results: In the observation group, the white blood cell count decreased after treatment with 14.6%, while in the control group, only the white blood cell count decreased by 1.0%. Conclusion: Omeprazole can significantly reduce the number of white blood cells in patients with cirrhosis.